Details for Patent: 11,666,576
✉ Email this page to a colleague
Which drugs does patent 11,666,576 protect, and when does it expire?
Patent 11,666,576 protects TADLIQ and is included in one NDA.
This patent has nine patent family members in nine countries.
Drugs Protected by US Patent 11,666,576
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,666,576
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018397436 | ⤷ Sign Up | |||
| Brazil | 112020012986 | ⤷ Sign Up | |||
| Canada | 3086881 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
